1. Executive Summary

2. Global Top 27 Cancer Blockbuster Drugs Market Size & Analysis (2015 - 2025)

3. Global Top 27 Cancer Blockbuster Drugs Market Share & Y-o-YGrowth (%), 2015 - 2025

4. Key Drivers and Inhibitors of the Global Cancer Blockbuster Drugs Market
4.1 Market Drivers
4.2 Market Inhibitors

5. Global Top 27 Cancer Blockbuster Drugs Market Assessment & Opportunity, (2015 - 2025)
5.1 Imbruvica (Ibrutinib)
5.2 Revlimid (Lenalidomide)
5.3 Pomalyst/Imnovid (Pomalidomide)
5.4 Keytruda (Pembrolizumab)
5.5 Herceptin (Trastuzumab)
5.6 Avastin (Bevacizumab)
5.7 MabThera/Rituxan (Rituximab)
5.8 Perjeta (Pertuzumab)
5.9 Opdivo (Nivolumab)
5.10 Sprycel (Dasatinib)
5.11 Ibrance (Palbociclib)
5.12 Zytiga (Abiraterone acetate)
5.13 Tagrisso (Osimertinib)
5.14 Darzalex (Daratumumab)
5.15 Xtandi (Enzalutamide)
5.16 Jakafi/Jakavi (Ruxolitinib Phosphate)
5.17 Yervoy (Ipilimumab)
5.18 Alimta (Pemetrexed)
5.19 Gleevec/Glivec (Imatinib Mesylate)
5.20 Velcade (Bortezomib)
5.21 Tasigna (Nilotinib)
5.22 Xgeva (Denosumab)
5.23 Afinitor/Votubia (Everolimus)
5.24 Neulasta (Pegfilgrastim)
5.25 Exjade Jadenu (Deferasirox)
5.26 Sandostatin (Octreotide Acetate)
5.27 Faslodex (Fulvestrant)

6. Major Deals in Cancer Drugs Market
6.1 Collaboration Deals
6.2 Merger and Acquisitions
6.3 Licensing Agreement
6.4 Partnership Deals
6.5 Distribution Agreement

7. Key Companies Analysis
7.1 Roche
7.1.1 Business Overview
7.1.2 Recent Development
7.2 Bristol-Myers Squibb
7.2.1 Business Overview
7.2.2 Recent Development
7.3 Pfizer
7.3.1 Business Overview
7.3.2 Recent Development
7.4 Eli Lilly and Company
7.4.1 Business Overview
7.4.2 Recent Development
7.5 Merck
7.5.1 Business Overview
7.5.2 Recent Development
7.6 Johnson & Johnson
7.6.1 Business Overview
7.6.2 Recent Development
7.7 AstraZeneca
7.7.1 Business Overview
7.7.2 Recent Development
7.8 Celgene
7.8.1 Business Overview
7.8.2 Recent Development
7.9 Novartis
7.9.1 Business Overview
7.9.2 Recent Developmnet
7.10 Amgen
7.10.1 Business Overview
7.10.2 Recent Development